The current financial score of Dr Reddy's Laboratories Ltd is 7.24. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 907.30M, representing a year-over-year decrease of 10.08%, while its net profit experienced a year-over-year decrease of 41.23%.
The current valuation score of Dr Reddy's Laboratories Ltd is 8.15. Its current P/E ratio is 25.58, which is 3.15% below the recent high of 26.39 and 39.84% above the recent low of 15.39.
The current earnings forecast score of Dr Reddy's Laboratories Ltd is 7.00. The average price target is 14.07, with a high of 15.70 and a low of 11.40.
The current price momentum score of Dr Reddy's Laboratories Ltd is 4.11. Currently, the stock price is trading between the resistance level at 15.68 and the support level at 13.37, making it suitable for range-bound swing trading.
The current institutional shareholding score of Dr Reddy's Laboratories Ltd is 3.00. The latest institutional shareholding proportion is 14.05%, representing a quarter-over-quarter increase of 1.56%.
The current risk assessment score of Dr Reddy's Laboratories Ltd is 8.60. The company's beta value is 0.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.